Chase Hall Joins Polarean as Chief Medical Advisor

Polarean Imaging plc has welcomed Chase Hall, M.D., as chief medical advisor.

“I am delighted to welcome Dr. Hall to Polarean as our new chief medical advisor,” Polarean CEO Christopher von Jako, Ph.D, said. “As a leading expert in pulmonary medicine as well as a champion of our Xenon MRI technology platform, Dr. Hall is a perfect fit for the company. His appointment represents a significant step in growing the Polarean team as we look to expand Xenon MRI to more clinical and research sites.”
 
Dr. Hall is an associate professor, Pulmonary, Critical Care and Sleep Medicine, at the University of Kansas Medical Center in the Division of Pulmonary and Critical Care. He also serves as associate director at the University of Kansas Interstitial Lung Disease and Rare Lung Disease Clinic. Dr. Hall’s research focus has been on establishing imaging biomarkers in respiratory disease, utilizing Xenon MRI. In his lab, he is currently working to utilize Xenon MRI as a sensitive measure of treatment response in a number of respiratory diseases, as well as rapid image acquisition protocols and fully automated image analysis programs. In addition, Dr. Hall is a member of the Xenon MRI Clinical Trials Consortium, a growing collaboration of 13 clinical research sites; its activities include the harmonization and standardization of Xenon imaging protocols for multi-center clinical trials, training of new sites establishing Xenon MRI programs, and growing awareness and expertise in the field. 
 
As chief medical advisor, Dr. Hall will guidw Polarean’s clinical development strategy and medical education initiatives with fellow clinicians and professional societies. He will leverage his experience while maintaining his clinical pulmonology practice, providing valuable insights to help Polarean address unmet medical needs in pulmonary care.
 
Dr. Hall earned his medical degree from the University of Kansas School of Medicine and completed his residency in Internal Medicine and fellowship training in Pulmonary and Critical Care at Washington University School of Medicine in St. Louis. He serves as a peer-reviewer for many prestigious journals, such as Academic Radiology and The American Journal of Respiratory and Critical Care Medicine.
 
“For several years, I have been deeply interested in the potential of Xenon MRI to assist pulmonary clinicians and the patients we treat. There is a significant unmet need in pulmonary medicine for imaging technology that can better characterize disease, monitor response to therapy, and guide interventional procedures,” Hall stated. “I am excited to join Polarean to help guide the clinical development and implementation of this technology in pulmonary medicine.”

Polarean researches, develops, and commercializes imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarization system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations
 
Polarean is a revenue-generating medical imaging technology company improving pulmonary medicine through direct visualization of lung function by introducing the power and safety of MRI to the respiratory healthcare community. The company strives to optimize lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW, which is now approved by the U.S. Food and Drug Administration.  Founded in 2012, with offices in Durham, N.C., and London, United Kingdom, Polarean is committed to increasing global awareness of and access to its XENOVIEW MRI technology platform.